HSV-1 amplicon vectors: A promising and versatile tool for gene delivery

Expert Opinion on Biological Therapy

Volumn 7, Issue 7, 2007, Pages 975-995

  Cuchet, Delphine ^a   Potel, Corinne ^a   Thomas, Joëlle ^a   Epstein, Alberto L ^a  

^a NONE

Author keywords

Amplicon; Cancer therapy; Gene therapy; Herpes simplex virus 1; Hybrid vectors; Neurological applications; Vaccination

Indexed keywords

DNA; VIRUS VACCINE; VIRUS VECTOR;

AMPLICON; ANTIANGIOGENIC GENE THERAPY; ATAXIA; CANCER; CELL CULTURE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MOLONEY LEUKEMIA ONCOVIRUS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; TUMOR;

ANIMALS; ATAXIA; COGNITION; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEURONAL PLASTICITY; PARKINSON DISEASE; PRODRUGS; PROMOTER REGIONS (GENETICS); RECOMBINATION, GENETIC; TRANSGENES; VACCINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

HUMAN HERPESVIRUS 1;

EID: 34547670597     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.7.975     Document Type: Review

References (161)

1. SPAETE RR, FRENKEL N: The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell (1982) 30(1):295-304. •• First description of amplicon vectors.
2. DEISS LP, CHOU J, FRENKEL N: Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA. J Virol (1986) 59(3):605-618.
3. SPAETE RR, FRENKEL N: The herpes simplex virus amplicon: analyses of cis-acting replication functions. Proc. Natl. Acad. Sci. USA (1985) 82(3):694-698.
4. VLAZNY DA, FRENKEL N: Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes. Proc. Natl Acad. Sci. USA (1981) 78(2):742-746.
5. BOEHMER PE, LEHMAN IR: Herpes simplex virus DNA replication. Ann. Rev. Biochem. (1997) 66:347-384.
6. KWONG AD, FRENKEL N: Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucaryotic DNA sequences. J. Virol. (1984) 51(3):595-603.
7. GELLER AI: A new method to propagate defective HSV-1 vectors. Nucleic Acids Res. (1988) 16(12):5690.
8. GELLER AI, KEYOMARSI K, BRYAN J, PARDEE AB: An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc. Natl. Acad. Sci. USA (1990) 87(22):8950-8954.
9. LIM F, HARTLEY D, STARR P et al.: Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques (1996) 20(3):460-469.
10. PECHAN PA, FOTAKI M, THOMPSON RL et al.: A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum. Gene Ther. (1996) 7(16):2003-2013.
11. ZHANG X, O'SHEA H, ENTWISLE C et al.: An efficient selection system for packaging herpes simplex virus amplicons. J. Gen. Virol. (1998) 79(Part 1):125-131.
12. LOGVINOFF C, EPSTEIN AL: Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase. Virology (2000) 267(1):102-110.
13. ZAUPA C, REVOL-GUYOT V, EPSTEIN AL: Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum. Gene Ther. (2003) 14(11):1049-1063. •• Production of amplicons using the improved Cre/loxP helper system.
14. CUNNINGHAM C, DAVISON AJ: A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology (1993) 197(1):116-124.
15. FRAEFEL C, SONG S, LIM F et al.: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. (1996) 70(10):7190-7197.
16. HORSBURGH BC, HUBINETTE MM, QIANG D, MACDONALD ML, TUFARO F: Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Ther. (1999) 6(5):922-930.
17. SAEKI Y, ICHIKAWA T, SAEKI A et al.: Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. (1998) 9(18):2787-2794.
18. STAVROPOULOS TA, STRATHDEE CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Virol. (1998) 72(9):7137-7143.
19. SAEKI Y, BREAKEFIELD XO, CHIOCCA EA: Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol. Med. (2003) 76:51-60.
20. SAEKI Y, FRAEFEL C, ICHIKAWA T, BREAKEFIELD XO, CHIOCCA EA: Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. (2001) 3(4):591-601. •• Production of helper-free amplicons using the improved BAC system.
21. PIN RH, REINBLATT M, BOWERS WJ, FEDEROFF HJ, FONG Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J. Gastrointest. Surg. (2004) 8(7):812-822; discussion 822-813.
22. REINBLATT M, PIN RH, BOWERS WJ, FEDEROFF HJ, FONG Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol. (2005) 12(12):1025-1036.
23. WILLIS RA, BOWERS WJ, TURNER MJ et al.: Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum. Gene Ther. (2001) 12(15):1867-1879.
24. JARNAGIN WR, DELMAN K, KOOBY D et al.: Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann. Surg. (2000) 231(5):762-771.
25. KARPOFF HM, KOOBY D, D'ANGELICA M et al.: Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production. Cancer Gene Ther. (2000) 7(4):581-588.
26. TODA M, MARTUZA RL, RABKIN SD: Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. (2000) 2(4):324-329.
27. D'ANGELICA M, TUNG C, ALLEN P et al.: Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. Mol. Med. (1999) 5(9):606-616.
28. TOLBA KA, BOWERS WJ, ELING DJ et al.: HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol. Ther. (2002) 6(4):455-463.
29. TOLBA KA, BOWERS WJ, HILCHEY SP et al.: Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood (2001) 98(2):287-295.
30. ZIBERT A, THOMASSEN A, MULLER L et al.: Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Gene Ther. (2005) 12(23):1707-1717.
31. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. (1995) 1(9):938-943.
32. CAREW JF, KOOBY DA, HALTERMAN MW et al.: A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol. Ther. (2001) 4(3):250-256.
33. ZAGER JS, DELMAN KA, MALHOTRA S et al.: Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. (2001) 7(8):561-568.
34. PECHAN PA, HERRLINGER U, AGHI M, JACOBS A, BREAKEFIELD XO: Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J. Gene Med. (1999) 1(3):176-185.
35. ZHANG L, DAIKOKU T, OHTAKE K et al.: Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10. J. Virol. Methods (2006) 137(2):177-183.
36. TAKAKUWA H, GOSHIMA F, NOZAWA N et al.: Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. (2003) 148(4):813-825.
37. RAINOV NG, SENA-ESTEVES M, FRAEFEL C et al.: A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv. Exp. Med. Biol. (1998) 451:393-403.
38. WANG S, QI J, SMITH M, LINK CJ: Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir. Cancer Gene Ther. (2002) 9(1):1-8.
39. JACOBS AH, WINKELER A, HARTUNG M et al.: Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum. Gene Ther. (2003) 14(3):277-297.
40. BOUTELL C, CANNING M, ORR A, EVERETT RD: Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J. Virol. (2005) 79(19):12342- 12354.
41. CUCHET D, FERRERA R, LOMONTE P, EPSTEIN AL: Characterization of antiproliferative and cytotoxic properties of the HSV-1 immediate-early ICP0 protein. J. Gene Med. (2005) 7(9):1187-1199.
42. HO IA, HUI KM, LAM PY: Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum. Gene Ther. (2004) 15(5):495-508.
43. HO IA, HUI KM, LAM PY: Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther. (2006) 13(1):44-52.
44. SHAH K, TANG Y, BREAKEFIELD X, WEISSLEDER R: Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene (2003) 22(44):6865-6872.
45. SHAH K, TUNG CH, BREAKEFIELD XO, WEISSLEDER R: In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther. (2005) 11(6):926-931.
46. SHAH K, BREAKEFIELD XO: HSV amplicon vectors for cancer therapy. Curr. Gene Ther. (2006) 6(3):361-370.
47. HOSHI M, HARADA A, KAWASE T, UYEMURA K, YAZAKI T: Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy. Cancer Gene Ther. (2000) 7(5):799-805.
48. SAYDAM O, GLAUSER DL, HEID I et al.: Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol. Ther. (2005) 12(5):803-812.
49. GESCHWIND MD, HARTNICK CJ, LIU W et al.: Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. Hum. Gene Ther. (1996) 7(2):173-182.
50. STAECKER H, GABAIZADEH R, FEDEROFF H, VAN DE WATER TR: Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol. Head Neck Surg. (1998) 119(1):7-13.
51. GARRIDO JJ, ALONSO MT, LIM F et al.: Defining responsiveness of avian cochlear neurons to brain-derived neurotrophic factor and nerve growth factor by HSV-1-mediated gene transfer. J. Neurochem. (1998) 70(6):2336-2346.
52. CHEN X, FRISINA RD, BOWERS WJ, FRISINA DR, FEDEROFF HJ: HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol. Ther. (2001) 3(6):958-963.
53. BOWERS WJ, CHEN X, GUO H et al.: Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol. Ther. (2002) 6(1):12-18.
54. HARVEY BK, CHANG CF, CHIANG YH et al.: HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp. Neurol. (2003) 183(1):47-55.
55. LAWRENCE MS, HO DY, SUN GH, STEINBERG GK, SAPOLSKY RM: Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J. Neurosci. (1996) 16(2):486-496.
56. ANTONAWICH FJ, FEDEROFF HJ, DAVIS JN: BCL-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Exp. Neurol. (1999) 156(1):130-137.
57. LAWRENCE MS, MCLAUGHLIN JR, SUN GH et al.: Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J. Cereb. Blood Flow Metab. (1997) 17(7):740-744.
58. LINNIK MD, ZAHOS P, GESCHWIND MD, FEDEROFF HJ: Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke (1995) 26(9):1670-1674; discussion 1675.
59. ZHAO H, YENARI MA, CHENG D et al.: Bcl-2 transfection via herpes simplex virus blocks apoptosis-inducing factor translocation after focal ischemia in the rat. J. Cereb. Blood Flow Metab. (2004) 24(6):681-692.
60. HOEHN B, RINGER TM, XU L et al.: Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J. Cereb. Blood Flow Metab. (2001) 21(11):1303-1309.
61. LIM MC, BROOKE SM, SAPOLSKY RM: gp120 neurotoxicity fails to induce heat shock defenses, while the over expression of hsp70 protects against gp120. Brain Res. Bull. (2003) 61(2):183-188.
62. LAMIGEON C, PROD'HON C, DE FRIAS V, MICHOUDET C, JACQUEMONT B: Enhancement of neuronal protection from oxidative stress by glutamic acid decarboxylase delivery with a defective herpes simplex virus vector. Exp. Neurol. (2003) 184(1):381-392.
63. HO DY, MOCARSKI ES, SAPOLSKY RM: Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc. Natl. Acad. Sci. USA (1993) 90(8):3655- 3659.
64. LAWRENCE MS, HO DY, DASH R, SAPOLSKY RM: Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss. Proc. Natl Acad. Sci. USA (1995) 92(16):7247-7251.
65. HO DY, SAYDAM TC, FINK SL, LAWRENCE MS, SAPOLSKY RM: Defective herpes simplex virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insults. J. Neurochem. (1995) 65(2):842-850.
66. MEIER TJ, HO DY, PARK TS, SAPOLSKY RM: Gene transfer of calbindin D28k cDNA via herpes simplex virus amplicon vector decreases cytoplasmic calcium ion response and enhances neuronal survival following glutamatergic challenge but not following cyanide. J. Neurochem. (1998) 71(3):1013-1023.
67. PHILLIPS RG, MEIER TJ, GIULI LC et al.: Calbindin D28K gene transfer via herpes simplex virus amplicon vector decreases hippocampal damage in vivo following neurotoxic insults. J. Neurochem. (1999) 73(3):1200-1205.
68. WANG H, CHENG E, BROOKE S, CHANG P, SAPOLSKY R: Over-expression of antioxidant enzymes protects cultured hippocampai and cortical neurons from necrotic insults. J. Neurochem. (2003) 87(6):1527-1534.
69. ZEMLYAK I, NIMON V, BROOKE S et al.: Gene therapy in the nervous system with superoxide dismutase. Brain Res. (2006) 1088(1):12-18.
70. DURING MJ, NAEGELE JR, O'MALLEY KL, GELLER AI: Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science (1994) 266(5189):1399-1403. • First use of amplicons for in vivo experimental gene therapy of PD.
71. SUN M, ZHANG GR, KONG L et al.: Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum. Gene Ther. (2003) 14(5):415-424.
72. SUN M, KONG L, WANG X et al.: Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum. Gene Ther. (2004) 15(12):1177-1196.
73. SUN M, KONG L, WANG X et al.: Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinsons disease. Brain Res. (2005) 1052(2):119-129.
74. CORTES ML, BAKKENIST CJ, DI MARIA MV, KASTAN MB, BREAKEFIELD XO: HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Ther. (2003) 10(16):1321-1327.
75. CORTES ML, OEHMIG A, PERRY KF, SANFORD JD, BREAKEFIELD XO: Expression of human ATM cDNA in ATM-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience (2006) 141(3):1247-1256.
76. QI J, SHACKELFORD R, MANUSZAK R et al.: Functional expression of ATM gene carried by HSV amplicon vector in vitro and in vivo. Gene Ther. (2004) 11(1):25-33.
77. GOMEZ-SEBASTIAN S, GIMENEZ-CASSINA A, DIAZ-NIDO J, LIM F, WADE-MARTINS R: Infectious delivery and expression of a 135 kb human FRDA genomic DNA Locus complements Friedreich's ataxia deficiency in human cells. Mol. Ther. (2007) 15(2):248-254.
78. WHITLEY RJ: Herpes simplex viruses. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001):2461-2510.
79. SAMADY L, COSTIGLIOLA E, MACCORMAC L et al.: Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs-HSV vectors for dendritic cell-mediated immunotherapy. J. Virol. (2003) 77(6):3768-3776.
80. + T lymphocytes. Cell (1994) 77(4):525-535.
81. HOCKNELL PK, WILEY RD, WANG X et al.: Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. (2002) 76(11):5565-5580. • First use of amplicons as vaccine vectors.
82. WANG X, WILEY RD, EVANS TG et al.: Cellular immune responses to helper-free HSV-1 amplicon panicles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine (2003) 21(19-20):2288-2297.
83. GORANTLA S, SANTOS K, MEYER V et al.: Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus Type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J. Virol. (2005) 79(4):2124-2132.
84. SANTOS K, DUKE CM, RODRIGUEZ-COLON SM et al.: Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine (2007) 25(9):1634-1646.
85. BOWERS WJ, MASTRANGELO MA, STANLEY HA et al.: HSV amplicon-mediated AP vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging (2005) 26(4):393-407.
86. TYLER CM, WUERTZER CA, BOWERS WJ, FEDEROFF HJ: HSV amplicons: neuro applications. Curr. Gene Ther. (2006) 6(3):337-350.
87. BROCKMAN MA, KNIPE DM: Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. Virol. (2002) 76(8):3678-3687.
88. LAUTERBACH H, RIED C, EPSTEIN AL, MARCONI P, BROCKER T: Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J. Gen. Virol. (2005) 86(Part 9):2401-2410.
89. JERUSALINSKY D, EPSTEIN AL: Amplicon vectors as outstanding tools to study and modify cognitive functions. Curr. Gene Ther. (2006) 6(3):351-360.
90. NEILL JC, SARKISIAN MR, WANG Y et al.: Enhanced auditory reversal learning by genetic activation of protein kinase C in small groups of rat hippocampai neurons. Brain Res. Mol. Brain Res. (2001) 93(2):127-136.
91. CHELI VT, ADROVER MF, BLANCO C et al.: Gene transfer of NMDAR1 subunit sequences to the rat CNS using herpes simplex virus vectors interfered with habituation. Cell Mol. Neurobiol. (2002) 22(3):303-314.
92. ADROVER MF, GUYOT-REVOL V, CHELI VT et al.: Hippocampal infection with HSV-1-derived vectors expressing an NMDAR1 antisense modifies behavior. Genes Brain Behav. (2003) 2(2):103-113.
93. CHELI V, ADROVER M, BLANCO C et al.: Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning. J. Neurochem. (2006) 97(Suppl. 1):68-73.
94. RUMPEL S, LEDOUX J, ZADOR A, MALINOW R: Postsynaptic receptor trafficking underlying a form of associative learning. Science (2005) 308(5718):83-88.
95. YUAN Q, HARLEY CW, BRUCE JC, DARBY-KING A, MCLEAN JH: Isoproterenol increases CREB phosphorylation and olfactory nerve-evoked potentials in normal and 5-HT-depleted olfactory bulbs in rat pups only at doses that produce odor preference learning. Learn. Mem. (2000) 7(6):413-421.
96. BRIGHTWELL JJ, SMITH CA, COUNTRYMAN RA, NEVE RL, COLOMBO PJ: Hippocampal overexpression of mutant creb blocks long-term, but not short-term memory for a socially transmitted food preference. Learn. Mem. (2005) 12(1):12-17.
97. POO MM: Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. (2001) 2(1):24-32.
98. THOENEN H: Neurotrophins and neuronal plasticity. Science (1995) 270(5236):593-598.
99. LAD SP, NEET KE, MUFSON EJ: Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. (2003) 2(5):315-334.
100. SALEHI A, DELCROIX JD, SWAAB DF: Alzheimer's disease and NGF signaling. J. Neural. Transm. (2004) 111(3):323-345.
101. SCOTT SA, CRUTCHER KA: Nerve growth factor and Alzheimer's disease. Rev. Neurosci. (1994) 5(3):179-211.
102. BROOKS AI, CORY-SLECHTA DA, BOWERS WJ, MURG SL, FEDEROFF HJ: Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum. Gene Ther. (2000) 11(17):2341-2352.
103. BERGOLD PJ, CASACCIA-BONNEFIL P, ZENG XL, FEDEROFF HJ: Transsynaptic neuronal loss induced in hippocampai slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc. Natl. Acad. Sci. USA (1993) 90(13):6165-6169.
104. VICARIO I, SCHIMMANG T: Transfer of FGF-2 via HSV-1-based amplicon vectors promotes efficient formation of neurons from embryonic stem cells. J. Neurosci. Methods (2003) 123(1):55-60.
105. RIETHMACHER D, LIM F, SCHIMMANG T: Efficient transfer of HSV-1 amplicon vectors into embryonic stem cells and their derivatives. Methods Mol. Biol. (2006) 329:265-272.
106. SAVARD N, COSSET FL, EPSTEIN AL: Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors. J. Virol. (1997) 71(5):4111-4117. • First development of hybrid amplicons expressing virus-like particles.
107. PARRISH E, PELTÉKIAN E, DICKSON G, EPSTEIN AL, GARCIA L: Cell engineering for muscle gene therapy: extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes. Cytotechnology (1999) 30:173-180.
108. SENA-ESTEVESM M, SAEKI Y, CAMP SM, CHIOCCA EA, BREAKEFIELD XO: Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol. (1999) 73(12):10426-10439.
109. HONG Z, FERRARI E, WRIGHT-MINOGUE J et al.: Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J. Virol. (1996) 70(7):4261-4268.
110. KALAMVOKI M, MAVROMARA P: Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. J. Virol. (2004) 78(21):11865-11878.
111. TSITOURA E, LUCAS M, REVOL-GUYOT V et al.: Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J. Gen. Virol. (2002) 83(Part 3):561-566.
112. TSITOURA E, GEORGOPOULOU U, MAVROMARA P: HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins. Curr. Gene Ther. (2006) 6(3):393-398.
113. TSAI DJ, HO JJ, OZAWA CR, SAPOLSKY RM: Long-term expression driven by herpes simplex virus type-1 amplicons may fail due to eventual degradation or extrusion of introduced transgenes. Exp. Neurol. (2000) 165(1):58-65.
114. SUZUKI M, KASAI K, SAEKI Y: Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J. Virol. (2006) 80(7):3293-3300. • Identification of bacterial DNA sequences as one major source of silencing of transgenic expression.
115. CHEN ZY, HE CY, EHRHARDT A, KAY MA: Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. (2003) 8(3):495-500. • Identification of bacterial DNA sequences as one major source of silencing of transgenic expression.
116. EVERETT RD, BOUTELL C, ORR A: Phenotype of a herpes simplex virus Type 1 mutant that fails to express immediate-early regulatory protein ICPO. J. Virol. (2004) 78(4):1763-1774.
117. EVERETT RD, RECHTER S, PAPIOR P et al.: PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. (2006) 80(16):7995-8005.
118. CHELBI-ALIX MK, DE THE H: Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene (1999) 18(4):935-941.
119. GU H, ROIZMAN B: The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc. Natl. Acad. Sci. USA (2003) 100(15):8963- 8968.
120. LU B, FEDEROFF HJ: Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum. Gene Ther. (1995) 6(4):419-428.
121. FOTAKI ME, PINK JR, MOUS J: Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther. (1997) 4(9):901-908.
122. HO DY, MCLAUGHLIN JR, SAPOLSKY RM: Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system. Brain Res. Mol. Brain Res. (1996) 41(1-2):200- 209.
123. WANG S, PETRAVICZ J, BREAKEFIELD XO: Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol. Ther. (2003) 7(6):790-800.
124. KAPLITT MG, KWONG AD, KLEOPOULOS SP et al.: Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. USA (1994) 91(19):8979-8983.
125. SONG S, WANG Y, BAK SY et al.: An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J. Neurochem. (1997) 68(5):1792-1803.
126. HIBBITT OC, WADE-MARTINS R: Delivery of large genomic DNA inserts > 100 kb using HSV-1 amplicons. Curr. Gene Ther. (2006) 6(3):325-336.
127. WADE-MARTINS R, SAEKI Y, CHIOCCA EA: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol. Ther. (2003) 7(5 Part 1):604-612.
128. JOHNSTON KM, JACOBY D, PECHAN PA et al.: HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. (1997) 8(3):359-370. • Development of HSV-1/AAV hybrid system to induce targetted integration of the transgenic cassette.
129. FRAEFEL C, JACOBY DR, LAGE C et al.: Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol. Med. (1997) 3(12):813-825.
130. LAM P, HUI KM, WANG Y et al.: Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther (2002) 13(18):2147-2159.
131. WANG Y, CAMP SM, NIWANO M et al.: Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J. Virol. (2002) 76(14):7150-7162.
132. HEISTER T, HEID I, ACKERMANN M, FRAEFEL C: Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J. Virol. (2002) 76(14):7163-7173.
133. BAKOWSKA JC, DI MARIA MV, CAMP SM et al.: Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Ther. (2003) 10(19):1691-1702.
134. HEILBRONN R, BURKLE A, STEPHAN S, ZUR HAUSEN H: The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J. Virol. (1990) 64(6):3012-3018.
135. GLAUSER DL, SAYDAM O, BALSIGER NA et al.: Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins. J. Virol. (2005) 79(19):12218-12230.
136. LIU Q, PEREZ CF, WANG Y: Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J. Virol. (2006) 80(4):1672-1679.
137. GLAUSER DL, ACKERMANN M, SAYDAM O, FRAEFEL C: Chimeric herpes simplex virus/adeno-associated virus amplicon vectors. Curr. Gene Ther. (2006) 6(3):315-324.
138. IVICS Z, HACKETT PB, PLASTERK RH, IZSVAK Z: Molecular reconstruction of sleeping beauty, a Tcl-like transposon from fish, and its transposition in human cells. Cell (1997) 91(4):501-510.
139. BOWERS WJ, MASTRANGELO MA, HOWARD DF et al.: Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol. Ther. (2006) 13(3):580-588.
140. WANG S, DI S, YOUNG WB, JACOBSON C, LINK CJ Jr: A novel herpesvirus amplicon system for in vivo gene delivery. Gene Ther. (1997) 4(11):1132-1141.
141. WANG S, VOS JM: A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J. Virol. (1996) 70(12):8422- 8430. •• Development of HSV-1/EBV hybrid vectors to avoid dilution of the vector genome in dividing cells.
142. WADE-MARTINS R, SMITH ER, TYMINSKI E, CHIOCCA EA, SAEKI Y: An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol. (2001) 19(11):1067-1070. •• First development of amplicon vectors delivering entire genomic loci.
143. MULLER L, SAYDAM O, SAEKI Y, HEID I, FRAEFEL C: Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol. Methods (2005) 123(1):65-72.
144. TSIMBOURI P, DROTAR ME, COY JL, WILSON JB: Bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene (2002) 21(33):5182-5187.
145. LARIN Z, MEJIA JE: Advances in human artificial chromosome technology. Trends Genet. (2002) 18(6):313-319.
146. MORALLI D, SIMPSON KM, WADE-MARTINS R, MONACO ZL: A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors. EMBO Rep. (2006) 7(9):911-918. • Amplicon delivery of HACs.
147. FERRERA R, CUCHET D, ZAUPA C et al.: Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1. J. Mol. Cell Cardiol. (2005) 38(1):219-223.
148. GELLER AI, FREESE A: Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli β-galactosidase. Proc. Natl. Acad. Sci. USA (1990) 87(3):1149-1153.
149. CARNICERO E, GARRIDO JJ, ALONSO MT, SCHIMMANG T: Roles of fibroblast growth factor 2 during innervation of the avian inner ear. J. Neurochem. (2001) 77(3):786-795.
150. VOGTLIN A, FRAEFEL C, KOCHERHANS R et al.: HSV-1-based amplicon particles are able to transduce cells of feline origin with genes encoding biologically functional feline IL-10 or IL-6. Vet. Microbiol. (2002) 86(1-2):103-113.
151. BROOKS AD, NG B, LIU D et al.: Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy. Surgery (2001) 129(3):324- 334.
152. SCHWYZER M, FISCHER-BRACHER C, FRAEFEL C et al.: Transduction of Vero cells and bovine monocytes with a herpes simplex virus-1 based amplicon carrying the gene for the bovine herpes virus-1 Circ protein. Vet. Microbiol. (2002) 86(1-2):165-174.
153. RABINOVITCH A, SUAREZ-PINZON W, STRYNADKA K et al.: Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects β-cells from cytokine-induced destruction. Diabetes (1999) 48(6):1223-1229.
154. GELLER AI, BREAKEFIELD XO: A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science (1988) 241(4873):1667-1669.
155. LU B, GUPTA S, FEDEROFF H: Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. Hepatology (1995) 21(3):752-759.
156. AGUDO M, TREJO JL, LIM F et al.: Highly efficient and specific gene transfer to Purkinje cells in vivo using a herpes simplex virus I amplicon. Hum. Gene Ther. (2002) 13(5):665-674.
157. GIMENEZ-CASSINA A, LIM F, DIAZ-NIDO J: Gene transfer into Purkinje cells using herpesviral amplicon vectors in cerebellar cultures. Neurochem. Int. (2007) 50(1):181-188.
158. WANG SW, MU X, BOWERS WJ, KLEIN WH: Retinal ganglion cell differentiation in cultured mouse retinal explants. Methods (2002) 28(4):448-456.
159. FRAEFEL C, MENDES-MADEIRA A, MABON O et al.: In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors. Gene Ther. (2005) 12(16):1283-1288.
160. WANG Y, FRAEFEL C, PROTASI F et al.: HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes. Am. J. Physiol. Cell Physiol. (2000) 278(3):C619-626.
161. WANG Y, MUKHERJEE S, FRAEFEL C, BREAKEFIELD XO, ALLEN PD: Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Hum. Gene Ther. (2002) 13(2):261-273.